Lymphoma

被引：155

作者：

Mugnaini, Emiliano N. ^{[1
]}

Ghosh, Nilanjan ^{[1
]}

机构：

[1] Carolinas HealthCare Syst, Levine Canc Ctr, Dept Hematol Oncol & Blood Disorders, Lymphoma Div, 1021 Morehead Med Dr, Charlotte, NC 28204 USA

来源：

PRIMARY CARE | 2016年 / 43卷 / 04期

关键词：

Lymphoma; Hodgkin; Non-Hodgkin; Diffuse large B cell; Follicular; Burkitt; MALT; T cell; MANTLE-CELL LYMPHOMA; REFRACTORY HODGKINS LYMPHOMA; RESPONSE-ADAPTED THERAPY; PIVOTAL PHASE-II; PLUS RITUXIMAB; BRENTUXIMAB VEDOTIN; OPEN-LABEL; COMBINATION CHEMOTHERAPY; BURKITTS-LYMPHOMA; CHOP CHEMOTHERAPY;

D O I：

10.1016/j.pop.2016.07.012

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Lymphomas may be broadly divided into non-Hodgkin (90%) and Hodgkin (10%) types. Most lymphomas (90%) are of B cell origin but can also be T cell or natural killer cell. Clinical management of indolent and aggressive lymphomas is different. Aggressive lymphomas are more dangerous if left untreated yet a higher cell proliferation rate also renders them more chemosensitive, so they are managed with curative intent. Indolent lymphomas are, for the most part, incurable, such that quality of life must be balanced against toxicity of treatment in deciding when and how to treat.

引用

页码：661 / +

页数：16

共 51 条

[1]

[Anonymous], CANC STAT FACT SHEET

[2]

Ansell S, 2015, AM SOC HEM ANN M ORL, DOI 583

[3] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[4]

Armand P, 2015, AM SOC HEM ANN M ORL

[5] Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis [J].

Barnes, J. A. ;

LaCasce, A. S. ;

Feng, Y. ;

Toomey, C. E. ;

Neuberg, D. ;

Michaelson, J. S. ;

Hochberg, E. P. ;

Abramson, J. S. .

ANNALS OF ONCOLOGY, 2011, 22 (08) :1859-1864

[6] PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study [J].

Barrington, Sally F. ;

Kirkwood, Amy A. ;

Franceschetto, Antonella ;

Fulham, Michael J. ;

Roberts, Thomas H. ;

Almquist, Helen ;

Brun, Eva ;

Hjorthaug, Karin ;

Viney, Zaid N. ;

Pike, Lucy C. ;

Federico, Massimo ;

Luminari, Stefano ;

Radford, John ;

Trotman, Judith ;

Fossa, Alexander ;

Berkahn, Leanne ;

Molin, Daniel ;

D'Amore, Francesco ;

Sinclair, Donald A. ;

Smith, Paul ;

O'Doherty, Michael J. ;

Stevens, Lindsey ;

Johnson, Peter W. .

BLOOD, 2016, 127 (12) :1531-1538

[7] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].

BONADONNA, G ;

VALAGUSSA, P ;

SANTORO, A .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746

[8]

BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO

[9]

2-7

[10] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

← 1 2 3 4 5 6 →